FDA's Abilify Logic Invites 'Gamesmanship,' Otsuka Says
Otsuka Pharmaceutical Co. Ltd. is pressing the D.C. Circuit to undo U.S. Food and Drug Administration approval for a rival version of the company's schizophrenia drug Abilify Maintena, saying the move...To view the full article, register now.
Already a subscriber? Click here to view full article